A web-based patient-reported system for monitoring symptoms after treatment for lung cancer is associated with significantly better overall survival than standard scheduled imaging, trial results show.
The level of mesenchymal epithelial transition factor copy number gain does not affect response to tyrosine kinase inhibitors in patients with metastatic epidermal growth factor receptor-mutated non-small-cell lung cancer, research shows.
Individuals with stage IV non-small-cell lung cancer harboring anaplastic lymphoma kinase translocations can hope to achieve overall survival of nearly 7 years, suggests a US cohort analysis.
Combining a plasma-based microRNA signature with tumoral tissue expression of programmed cell death ligand 1 could help identify advanced non-small-cell lung cancer patients who are unlikely to benefit from immune checkpoint inhibition, suggests an exploratory study.
Taking proton pump inhibitors alongside tyrosine kinase inhibitors is associated with an increased mortality risk in older cancer patients, research indicates.
The presence of some autoimmune antibodies prior to treatment with programmed cell death protein 1 inhibitors is associated with both clinical benefit and immune-related adverse events in patients with non-small-cell lung cancer, researchers report.
Digital next-generation sequencing of circulating tumor DNA is a clinically useful option for advanced lung adenocarcinoma patients with insufficient tumor biopsy samples, say researchers.
Epidermal growth factor receptor-mutant non-small-cell lung cancer that transforms to small-cell lung cancer is characterized by a high rate of TP53 mutation and a lack of response to immunotherapy, among other features, show researchers.
Some patients with extensive-stage small-cell lung cancer may benefit from the addition of the poly(ADP ribose) polymerase inhibitor veliparib to standard chemotherapy, but further confirmation of its efficacy is needed, say researchers.
Adjuvant erlotinib significantly prolongs disease-free survival, compared with a historic benchmark, in patients with epidermal growth factor receptor-mutated stage IA–IIIA non-small-cell lung cancer, US research shows.
A network meta-analysis has ranked the safety of immune checkpoint inhibitors in cancer treatment, with atezolizumab revealed to have the best general safety profile.
Patients with ALK-positive advanced non-small-cell lung cancer respond to the third-generation ALK and ROS1 tyrosine kinase inhibitor lorlatinib irrespective of previous ALK tyrosine kinase inhibitor treatment status, phase II study data show.
A modeling study presented at the 2018 NCRI Conference in Glasgow, UK, estimates that around 38% of the survival difference between older and younger patients with lung cancer may be due undertreatment in the older age group.
The CTONG-1103 EMERGING trial investigators believe that neoadjuvant treatment with epidermal growth factor receptor–tyrosine kinase inhibitors for stage IIIA-N2 non-small-cell lung cancer warrants further investigation.
The ALESIA trial comprising treatment-naïve patients with advanced anaplastic lymphoma kinase translocation-positive non-small-cell lung cancer confirms the systemic and intracranial efficacy of alectinib over crizotinib in an Asian population.
Combining the highly selective MET inhibitor tepotinib with gefitinib could benefit patients with non-small-cell lung cancer that has progressed on first-line treatment with an EGFR–tyrosine kinase inhibitor and has high levels of MET, suggest phase II trial results.
Plasma-based next-generation sequencing may help to identify therapeutically targetable mutations in patients with metastatic non-small-cell lung cancer, suggests research published in JAMA Oncology.